Abstract
Purpose: The gastrointestinal (GI) tract is the most common site of extranodal disease in patients with systemic non-Hodgkin's lymphoma (NHL). Patients with systemic NHL and GI involvement associated with AIDS (GI-ARL) have a significantly worse prognosis than those without AIDS. We studied whether the introduction of HAART is associated with improved survival in patients with GI-ARL. Patients and Method: 36 patients with GI-ARL were identified from the tumor registries of a large municipal hospital in New York City and a tertiary care facility in western New York State. Of these, 28 patients did not receive HAART and 8 were treated with HAART. The primary endpoint was survival, which was defined as time from date of diagnosis of NHL until death from any cause. Results: Patients were analyzed based on whether or not they were treated with HAART. Kaplan-Meier analyst showed significantly better survival in patients with GI-ARL who were concurrently treated with HAART (p = .014). Median survival was 5 months for the no-HAART group and 30 months for the HAART group. Conclusion: In patients with GI-ARL who were treated with chemotherapy, concurrent therapy with HAART therapy was associated with improved survival.
Original language | English (US) |
---|---|
Pages (from-to) | 140-145 |
Number of pages | 6 |
Journal | HIV Clinical Trials |
Volume | 5 |
Issue number | 3 |
DOIs | |
State | Published - May 2004 |
Keywords
- Gastrointestinal
- HAART
- HIV
- Lymphoma
ASJC Scopus subject areas
- Infectious Diseases
- Pharmacology (medical)